YM Biosciences Inc (YM)

YM BioSciences Inc., a drug development company, engages in developing hematology and cancer-related products. Its products include CYT387, a dual inhibitor of the JAK1 and JAK2 kinases, which has implicated in a family of hematological conditions known as myeloproliferative neoplasms, including myelofibrosis, as well in various other disorders comprising indications in hematology, oncology, and inflammatory diseases. The company is evaluating, CYT387, in a Phase I/II trial and a Phase II trial for the treatment of patients with myelofibrosis, a chronic debilitating disease in which a patient’s bone marrow is replaced by scar tissue. It is also developing nimotuzumab, a humanized monoclonal antibody, which is in various Phase II and III trials worldwide targeting epidermal growth factor receptor antibody. In addition, the company has various preclinical research programs underway with candidates from its library of compounds. YM BioSciences Inc. has collaboration agreements with Daiichi-Sankyo Pharmaceutical Co. Ltd., Kuhnil Pharmaceutical Company, Innogene Kalbiotech, Oncoscience AG, the Center of Molecular Immunology, Pulmokine Inc, and Cancer Therapeutics CRC Pty Ltd. The company was formerly known as York Medical Inc. and changed its name to YM Biosciences Inc. in February 2001. YM BioSciences Inc. was founded in 1994 and is headquartered in Mississauga, Canada. As of February 8, 2013, YM BioSciences Inc. operates as a subsidiary of Gilead Sciences Inc.